Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Enhance MD vs FuturHealth

Enhance MD
Graded #11

Higher grade

vs+19.200000000000003
FuturHealth
Graded #215

Lower grade

The verdict

Enhance MD takes it — 84.8/100 to 65.6/100.

Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEnhance MD +22
82
60
Dose & formulationEnhance MD +1
82
81
Clinical oversightEnhance MD +21
88
67
Labs & monitoringEnhance MD +29
90
61
FulfillmentEnhance MD +22
84
62
Contract termsEnhance MD +29
84
55
Enhance MD · left barFuturHealth · right bar

The numbers

MetricEnhance MDFuturHealth
WeighScore84.8/10065.6/100
GradeBC
Scorecard rank#11#215
Semaglutide$212/mo$199/mo (compounded)
Tirzepatide$280/moNot disclosed
CoverageNot publicly listedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Enhance MD

Graded #11 · B

Strengths

  • Transparent tiered pricing across sema, tirz, microdose, and combo
  • Dose-flat — the price does not step up as you titrate
  • Six-month lab testing plus provider-led care
  • NAD+ longevity adjacency available

Where it loses points

  • Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
  • No oral or sublingual route
  • States served are not published
  • Higher entry price than the cheapest compounded programs
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard